THE COVID-19 Pandemic: Pricing and Access Outlook for Future Innovative Drugs in Europe

Pricing and Market Access Impact of the COVID-19 Pandemic in Europe

Key takeaways: The COVID-19 outbreak puts healthcare systems at risk due to both acute operational impacts and broad financial disruptions, but the extent of the financial impact is still uncertain Similarly, austerity measures across the EU in response to the 2008 recession resulted in more restrictive healthcare budgets and pharmaceutical…

WHITE PAPER: The CEESP Economic Evaluation: Can Clinical Efficacy and Cost-effectiveness Co-exist in France?

The emergence of economic appraisals conducted by the Commission Évaluation Économique et de Santé Publique (CEESP) represents an important development in attaining market access to France. As of October 2013, manufacturers of certain innovative products are required to submit to an economic evaluation from the (CEESP) in addition to the…

Poster at ISPOR international on the role of indirect comparisons in the AMNOG evaluation procedure

The AMNOG assessment procedure requires that manufacturers submit indirect comparisons for the evaluation of molecules in the absence of the availability of direct comparisons versus the G-BA designated appropriate comparator(s). Although guidelines have been established on how indirect comparisons should be structured and carried out, the methodological robustness sought by…